Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Plus Therapeutics, Inc. (PSTV)
USD4.08
-0.20 (-4.67%)
US NASDAQ Healthcare Biotechnology
Address
4200 Marathon Boulevard 78756
Austin, TX, US
Austin, TX, US
CEO
Marc H. Hedrick
Website
plustherapeutics.com
IPO
2001-07-11
CIK 1095981 ISIN US72941H8060
Description
Plus Therapeutics, Inc. operates as a clinical-stage pharmaceutical company, dedicated to the development, manufacturing, and market introduction of therapeutic solutions for cancer patients and individuals with other serious illnesses. A cornerstone of their pipeline is Rhenium-186 NanoLiposome (R-186 NL), a patented radiotherapy specifically engineered to address difficult central nervous system (CNS) cancers, such as recurrent glioblastoma, leptomeningeal metastases, and various brain cancers affecting children. The company has also secured a licensing agreement with NanoTx, Corp. to advance and commercialize NanoTx's treatment for glioblastoma. Founded in 1996 and headquartered in Austin, Texas, the firm adopted its current name, Plus Therapeutics, Inc., in July 2019, having previously operated as Cytori Therapeutics, Inc.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD4.08
-0.20 (-4.67%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
310.2K
Beta
1.37
Float Shares
2.41M
Free Float %
99.8%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -8.85% | -13.51% | -17.84% | -25.11% | -55.81% | -59.02% | -37.35% | -94.88% | -99.34% | -100.00% | -100.00% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (4 ratings, all time)
Buy
Price Targets & DCF
Current price
4.08
Low
25.00
+512.7%
Consensus
25.00
+512.7%
Median
25.00
+512.7%
High
25.00
+512.7%
Ratings Trend (MoM)
80% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 1 | 0 |
| Buy | 3 | 0 |
| Hold | 1 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Price Target Summary
| Period | # Analysts | Avg Target |
|---|---|---|
| Last Month | — | — |
| Last Quarter | — | — |
| Last Year | 2 |
37.50
+819.1%
|
| All Time | 2 |
37.50
+819.1%
|
Quality scores
Altman Z-Score
-36.38
Distress
Piotroski F-Score
2 / 9
Weak
MOAT Score
2 / 10
No MOAT
Composite Rating
C
Overall Score
2 / 5
Medium
DCF Score
1 / 5
Low
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
3 / 5
Medium
P/E Score
1 / 5
Low
P/Book Score
3 / 5
Medium
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%-10.5% Q1'26: -2.9% (vs Q1'25)
-
EPS growth Biotechnology: +29.7%+87.7% ★ Q1'26: +100.0% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%-471.3% Q1'26: -686.4% (vs Q1'25)
-
EBIT margin Biotechnology: +0.0%-293.5% Q1'26: -692.5% (vs Q1'25)
-
ROIC Biotechnology: -16.1%— Q1'26: -294.7% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%+910.4% Q1'26: +1,140,500.2% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-0.06× Q1'26: -0.03× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 4 Rev. Ana. 3 EPS Ana. |
Dec 2027 4 Rev. Ana. 3 EPS Ana. |
Dec 2028 4 Rev. Ana. 4 EPS Ana. |
Dec 2029 3 Rev. Ana. 2 EPS Ana. |
Dec 2030 3 Rev. Ana. 2 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
11.66M
est: 13.52M (-13.8%)
|
11.38M
est: 11.73M (-3.0%)
|
6.41M
est: 7.70M (-16.7%)
|
2.98M
est: 6.70M (-55.5%)
|
7.00M
est: 6.50M (+7.7%)
|
303.0K
est: 301.5K (+0.5%)
|
224.0K
est: 1.35M (-83.4%)
|
4.91M
est: 5.51M (-10.8%)
|
5.82M
est: 5.53M (+5.4%)
|
5.21M
est: 5.20M (+0.3%)
|
5.79M
4.91M – 6.66M
+11.3% YoY
|
20.91M
16.05M – 25.78M
+261.5% YoY
|
47.73M
30.08M – 65.29M
+128.2% YoY
|
133.86M
84.35M – 183.09M
+180.4% YoY
|
186.12M
117.27M – 254.56M
+39.0% YoY
|
| EBITDA |
-14.27M
est: -8.11M (-76.0%)
|
-18.27M
est: -7.04M (-159.7%)
|
-18.49M
est: -4.62M (-300.1%)
|
-6.58M
est: -4.02M (-63.5%)
|
-532.0K
est: -3.90M (+86.4%)
|
-8.44M
est: -180.9K (-4,563.9%)
|
-18.85M
est: -809.6K (-2,228.6%)
|
-12.69M
est: -3.31M (-284.0%)
|
-8.40M
est: -3.32M (-153.3%)
|
-14.85M
est: -3.12M (-376.3%)
|
-3.47M
-3.99M – -2.95M
-11.3% YoY
|
-12.55M
-15.47M – -9.63M
-261.5% YoY
|
-28.64M
-39.17M – -18.05M
-128.2% YoY
|
-80.32M
-109.86M – -50.61M
-180.4% YoY
|
-111.67M
-152.74M – -70.36M
-39.0% YoY
|
| EBIT |
-15.37M
est: -8.11M (-89.4%)
|
-19.45M
est: -7.04M (-176.5%)
|
-20.64M
est: -4.62M (-346.7%)
|
-6.96M
est: -4.02M (-72.9%)
|
-1.43M
est: -3.90M (+63.4%)
|
-8.80M
est: -180.9K (-4,766.2%)
|
-19.56M
est: -809.6K (-2,316.5%)
|
-13.32M
est: -3.31M (-303.0%)
|
-9.25M
est: -3.32M (-179.0%)
|
-15.30M
est: -3.12M (-390.6%)
|
-3.47M
-3.99M – -2.95M
-11.3% YoY
|
-12.55M
-15.47M – -9.63M
-261.5% YoY
|
-28.64M
-39.17M – -18.05M
-128.2% YoY
|
-80.32M
-109.86M – -50.61M
-180.4% YoY
|
-111.67M
-152.74M – -70.36M
-39.0% YoY
|
| Net Income |
-18.74M
est: -155.95B (+100.0%)
|
-22.05M
est: -75.08B (+100.0%)
|
-22.69M
est: -41.59B (+99.9%)
|
-12.63M
est: -10.97B (+99.9%)
|
-10.89M
est: -2.89B (+99.6%)
|
-8.24M
est: -171.73M (+95.2%)
|
-20.28M
est: -85.19M (+76.2%)
|
-13.32M
est: -8.86M (-50.2%)
|
-12.98M
est: -144.90M (+91.0%)
|
-22.39M
est: -22.39M (+0.0%)
|
-11.96M
-12.27M – -11.65M
+46.6% YoY
|
-7.30M
-7.57M – -7.03M
+39.0% YoY
|
-784.4K
-1.45M – -122.6K
+89.3% YoY
|
7.31M
3.80M – 10.81M
+1,032.3% YoY
|
12.67M
6.58M – 18.72M
+73.2% YoY
|
| SGA |
12.43M
est: 184.17M (-93.3%)
|
12.17M
est: 159.77M (-92.4%)
|
11.19M
est: 104.90M (-89.3%)
|
6.22M
est: 91.32M (-93.2%)
|
5.29M
est: 88.55M (-94.0%)
|
6.41M
est: 4.11M (+56.0%)
|
9.53M
est: 18.38M (-48.2%)
|
8.54M
est: 54.32M (-84.3%)
|
9.94M
est: 54.51M (-81.8%)
|
12.13M
est: 51.24M (-76.3%)
|
57.04M
48.44M – 65.64M
+11.3% YoY
|
206.20M
158.25M – 254.15M
+261.5% YoY
|
470.64M
296.55M – 643.72M
+128.2% YoY
|
1.32B
831.65M – 1.81B
+180.4% YoY
|
1.84B
1.16B – 2.51B
+39.0% YoY
|
| EPS |
-374,898,500.00
est: -20,250.00 (-1,851,250.6%)
|
-240,000,000.00
est: -9,750.00 (-2,461,438.5%)
|
-131,345,500.00
est: -5,400.00 (-2,432,224.1%)
|
-32,617,500.00
est: -1,425.00 (-2,288,847.4%)
|
-3,101,250.00
est: -375.45 (-825,908.8%)
|
-697,500.00
est: -22.30 (-3,127,702.7%)
|
-288,750.00
est: -11.06 (-2,610,069.5%)
|
-106,000.00
est: -2.85 (-3,716,720.4%)
|
-48.75
est: -46.63 (-4.6%)
|
-7.19
est: -6.05 (-18.8%)
|
-3.85
-3.94 – -3.74
+36.4% YoY
|
-2.35
-2.43 – -2.26
+38.9% YoY
|
-0.29
-0.46 – -0.04
+87.8% YoY
|
2.35
1.22 – 3.47
+917.4% YoY
|
4.07
2.11 – 6.02
+73.2% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-15 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-14 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-13 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-12 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-11 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-08 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-07 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-06 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-05 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-04 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-01 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-30 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-29 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-28 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-27 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-24 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-23 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-22 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-21 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-20 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-17 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-16 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-21.73M
OE per share TTM
-751.44
Owner's Yield
-62.29%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
45.8%
Ownership Overview
Ownership breakdown
At a glance
Institutional holders
14
Total invested
938.4K
Insider transactions (90d)
1
Beneficial owners (>5%)
27
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 27-4413262 | 5.69M | 9.90% | 568.7K | — | 568.7K | — | OO | Maryland | 2024-06-05 | ↗ |
| 2 | Gregory Martinez | 1.51M | 7.40% | — | 1.51M | — | 1.51M | IN | Delaware | 2022-02-04 | ↗ |
| 3 | Parkman Healthcare Partners Holdings GP LLC | 1.51M | 7.40% | — | 1.51M | — | 1.51M | OO | Delaware | 2022-02-04 | ↗ |
| 4 | Parkman Healthcare Partners Holdings LP | 1.51M | 7.40% | — | 1.51M | — | 1.51M | PN | Delaware | 2022-02-04 | ↗ |
| 5 | Parkman Healthcare Partners LLC | 1.51M | 7.40% | — | 1.51M | — | 1.51M | IA, OO | Delaware | 2022-02-04 | ↗ |
| 6 | Identification Nos. of above persons (. | 568.7K | 9.90% | 568.7K | — | 568.7K | — | IN | States | 2024-06-05 | ↗ |
| 7 | Hudson Bay Capital Management LP | 550.0K | 3.46% | — | 550.0K | — | — | PN | State of Delaware | 2022-02-04 | ↗ |
| 8 | Sander Gerber | 550.0K | 3.46% | — | 550.0K | — | — | IN | United States | 2022-02-04 | ↗ |
| 9 | 13G | 369.4K | 9.90% | — | 369.4K | — | 369.4K | FI, CO | Texas | 2019-09-27 | ↗ |
| 10 | Daniel B. Asher | 300.0K | 1.90% | — | 300.0K | — | 300.0K | HC, IN | United States of America | 2022-02-11 | ↗ |
| 11 | Intracoastal Capital LLC | 300.0K | 1.90% | — | 300.0K | — | 300.0K | OO | Delaware | 2022-02-11 | ↗ |
| 12 | Mitchell P. Kopin | 300.0K | 1.90% | — | 300.0K | — | 300.0K | HC, IN | United States of America | 2022-02-11 | ↗ |
| 13 | Ande Bao | 230.8K | 4.83% | — | 230.8K | — | 230.8K | IN | United States | 2021-02-26 | ↗ |
| 14 | Andrew Brenner | 230.8K | 4.83% | — | 230.8K | — | 230.8K | IN | United States | 2021-02-26 | ↗ |
| 15 | NanoTx, Corp. | 230.8K | 4.83% | — | 230.8K | — | 230.8K | CO | Delaware | 2021-02-26 | ↗ |
| 16 | William Phillips | 230.8K | 4.83% | — | 230.8K | — | 230.8K | IN | United States | 2021-02-26 | ↗ |
| 17 | Inc. | 198.0K | 4.90% | — | 198.0K | — | 198.0K | FI, CO | Texas | 2020-02-14 | ↗ |
| 18 | Kassam | 198.0K | 4.90% | — | 198.0K | — | 198.0K | HC, IN | Texas | 2020-02-14 | ↗ |
| 19 | LLC | 198.0K | 4.90% | — | 198.0K | — | 198.0K | HC, OO | Texas | 2020-02-14 | ↗ |
| 20 | Management LP | 198.0K | 4.90% | — | 198.0K | — | 198.0K | IA, PN | Texas | 2020-02-14 | ↗ |
| 21 | Nathoo | 198.0K | 4.90% | — | 198.0K | — | 198.0K | HC, IN | Texas | 2020-02-14 | ↗ |
| 22 | Winson | 198.0K | 4.90% | — | 198.0K | — | 198.0K | HC, IN | Texas | 2020-02-14 | ↗ |
| 23 | Armistice Capital Master Fund Ltd. | 61.4K | 4.99% | — | 61.4K | — | 61.4K | CO | Delaware | 2019-10-03 | ↗ |
| 24 | Armistice Capital, LLC | 61.4K | 4.99% | — | 61.4K | — | 61.4K | IA, OO | Delaware | 2019-10-03 | ↗ |
| 25 | Steven Boyd | 61.4K | 4.99% | — | 61.4K | — | 61.4K | HC, IN | Delaware | 2019-10-03 | ↗ |
| 26 | Schonfeld Strategic Advisors LLC | 3.8K | 0.10% | — | 3.8K | — | — | IA | Delaware | 2020-02-14 | ↗ |
| 27 | Sassicaia Capital Advisers LLC | — | 0.00% | — | — | — | — | OO | Delaware | 2020-02-14 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
From
To
13F snapshot — 2026 Q1
Investors holding
14
-13 vs prev Q
New positions
5
Closed positions
18
Increased
7
Reduced
1
Put/Call ratio
0.00
Calls held
—
Puts held
—
Top institutional holders
| # | Investor | Shares / Δ | Mkt value / Δ | Own% / Δ | Weight% / Δ | Avg px / Perf. | Hold / Status |
|---|---|---|---|---|---|---|---|
| 1 | — | 2.28M +2.3M (+100.0%) | 1.17B +1.2B (+100.0%) | 2.12% +2.120 pp | 0.76% +0.764 pp | USD0.51 +0.0% | 1 qtrs NEW |
| 2 | VANGUARD GROUP INC | 2.28M +832.6K (+57.5%) | 1.17M +177.4K (+17.9%) | 2.12% -0.868 pp | 0.00% +0.000 pp | USD0.64 -20.3% | 11 qtrs — |
| 3 | BLACKROCK, INC. | 1.78M +1.3M (+278.4%) | 910.0K +589.1K (+183.6%) | 1.65% +0.684 pp | 0.00% +0.000 pp | USD0.56 -8.9% | 6 qtrs — |
| 4 | GEODE CAPITAL MANAGEMENT, LLC | 1.40M +589.5K (+72.5%) | 719.0K +163.0K (+29.3%) | 1.31% -0.375 pp | 0.00% +0.000 pp | USD0.65 -21.5% | 11 qtrs — |
| 5 | JANE STREET GROUP, LLC | 1.02M +1.0M (+100.0%) | 524.5K +524.5K (+100.0%) | 0.95% +0.953 pp | 0.00% +0.000 pp | USD0.51 +0.0% | 3 qtrs — |
| 6 | UBS GROUP AG | 875.8K +252.0K (+40.4%) | 448.4K +21.7K (+5.1%) | 0.82% -0.474 pp | 0.00% +0.000 pp | USD0.62 -17.7% | 4 qtrs — |
| 7 | VIRTU FINANCIAL LLC | 496.8K +496.8K (+100.0%) | 254.0K +254.0K (+100.0%) | 0.46% +0.462 pp | 0.01% +0.010 pp | USD0.51 +0.0% | 1 qtrs NEW |
| 8 | STATE STREET CORP | 468.9K +127.0K (+37.1%) | 240.2K +6.5K (+2.8%) | 0.44% -0.270 pp | 0.00% +0.000 pp | USD0.64 -20.3% | 2 qtrs — |
| 9 | NORTHERN TRUST CORP | 293.3K +27.8K (+10.5%) | 150.3K -31.3K (-17.2%) | 0.27% -0.276 pp | 0.00% +0.000 pp | USD0.67 -23.9% | 2 qtrs — |
| 10 | XTX TOPCO LTD | 248.6K +248.6K (+100.0%) | 127.3K +127.3K (+100.0%) | 0.23% +0.231 pp | 0.00% +0.003 pp | USD0.51 +0.0% | 1 qtrs NEW |
| 11 | CITADEL ADVISORS LLC | 185.1K +185.1K (+100.0%) | 94.8K +94.8K (+100.0%) | 0.17% +0.172 pp | 0.00% +0.000 pp | USD0.51 +0.0% | 1 qtrs NEW |
| 12 | TWO SIGMA SECURITIES, LLC | 55.9K +44.8K (+404.5%) | 28.6K +21.1K (+278.0%) | 0.05% +0.029 pp | 0.00% +0.003 pp | USD0.55 -7.3% | 5 qtrs — |
| 13 | CITIGROUP INC | 48.5K +48.5K (+100.0%) | 24.8K +24.8K (+100.0%) | 0.05% +0.045 pp | 0.00% +0.000 pp | USD0.51 +0.0% | 1 qtrs NEW |
| 14 | DAGCO, INC. | 25.9K +— (+0.0%) | 13.3K -4.4K (-25.1%) | 0.02% -0.029 pp | 0.00% -0.001 pp | USD0.68 -25.0% | 2 qtrs — |
| 15 | KESTRA ADVISORY SERVICES, LLC | 25.8K +— (+0.0%) | 13.2K -4.4K (-25.1%) | 0.02% -0.029 pp | 0.00% +0.000 pp | USD0.68 -25.0% | 2 qtrs — |
| 16 | ASHTON THOMAS PRIVATE WEALTH, LLC | 24.9K +24.9K (+100.0%) | 12.8K +12.8K (+100.0%) | 0.02% +0.023 pp | 0.00% +0.000 pp | USD0.51 +0.0% | 1 qtrs NEW |
| 17 | HIGHTOWER ADVISORS, LLC | 16.0K +16.0K (+100.0%) | 8.2K +8.2K (+100.0%) | 0.01% +0.015 pp | 0.00% +0.000 pp | USD0.51 +0.0% | 1 qtrs NEW |
| 18 | CAMBRIDGE INVESTMENT RESEARCH ADVISORS, INC. | 13.5K +3.0K (+28.1%) | 7.0K +— (+0.0%) | 0.01% -0.009 pp | 0.00% +0.000 pp | USD0.65 -21.5% | 2 qtrs — |
| 19 | J.W. COLE ADVISORS, INC. | 10.0K +10.0K (+100.0%) | 5.1K +5.1K (+100.0%) | 0.01% +0.009 pp | 0.00% +0.000 pp | USD0.51 +0.0% | 1 qtrs NEW |
| 20 | ROYAL BANK OF CANADA | 1.4K +1.4K (+100.0%) | 1.0K +1.0K (+100.0%) | 0.00% +0.001 pp | 0.00% +0.000 pp | USD0.51 +0.0% | 1 qtrs NEW |
| 21 | SBI SECURITIES CO., LTD. | 1.8K -1.5K (-44.9%) | 944.00 -1.3K (-58.7%) | 0.00% -0.005 pp | 0.00% +0.000 pp | USD0.51 +0.0% | 5 qtrs — |
| 22 | BANK OF AMERICA CORP /DE/ | 1.3K +434.0 (+52.2%) | 648.00 +81.0 (+14.3%) | 0.00% -0.001 pp | 0.00% +0.000 pp | USD0.63 -19.0% | 7 qtrs — |
| 23 | ADVISOR GROUP HOLDINGS, INC. | 133.00 +— (+0.0%) | 67.00 +8.0 (+13.6%) | 0.00% 0.000 pp | 0.00% +0.000 pp | USD2.02 -74.8% | 11 qtrs — |
| 24 | WELLS FARGO & COMPANY/MN | 53.00 +— (+0.0%) | 27.00 -9.0 (-25.0%) | 0.00% 0.000 pp | 0.00% +0.000 pp | USD0.34 +50.0% | 3 qtrs — |
| 25 | SOUND INCOME STRATEGIES, LLC | 28.00 +28.0 (+100.0%) | 8.00 +8.0 (+100.0%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD0.50 +2.0% | 1 qtrs NEW |
| 26 | BARCLAYS PLC | 2.00 +— (+0.0%) | 1.00 +— (+0.0%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD0.50 +2.0% | 4 qtrs — |
| 27 | DANSKE BANK A/S | 1.00 +— (+0.0%) | 1.00 +— (+0.0%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD— | 6 qtrs — |
| 28 | ALTIUM CAPITAL MANAGEMENT LP | — -918.9K (-100.0%) | — -628.3K (-100.0%) | 0.00% -1.899 pp | 0.00% -100.000 pp | USD— | 2 qtrs SOLD |
| 29 | MERCER GLOBAL ADVISORS INC /ADV | — -28.5K (-100.0%) | — -19.5K (-100.0%) | 0.00% -0.059 pp | 0.00% +0.000 pp | USD— | 2 qtrs SOLD |
| 30 | SCIENTECH RESEARCH LLC | — -146.7K (-100.0%) | — -100.3K (-100.0%) | 0.00% -0.303 pp | 0.00% -0.035 pp | USD— | 2 qtrs SOLD |
| 31 | GROUP ONE TRADING, L.P. | — -1.0 (-100.0%) | — -1.0 (-100.0%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD— | 11 qtrs SOLD |
| 32 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | — -67.3K (-100.0%) | — -46.0K (-100.0%) | 0.00% -0.139 pp | 0.00% +0.000 pp | USD— | 4 qtrs SOLD |
| 33 | TOWER RESEARCH CAPITAL LLC (TRC) | — -3.5K (-100.0%) | — -2.4K (-100.0%) | 0.00% -0.007 pp | 0.00% 0.000 pp | USD— | 11 qtrs SOLD |
Ownership breakdown by holder
ETF Ownership
Top ETFs holding this stock
Held by 2 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | iShares Micro-Cap ETF IWC | 0.01% | 93.6K | 0.60% |
| 2 | Vanguard Extended Market ETF VXF | 0.00% | 490.6K | 0.05% |
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
1.00
Neutral
Ratio by volume
0.42
Bearish
Buys
5
Sells
5
Shares acquired
267.1K
Shares disposed
630.4K
Cash buys
—
Cash sales
—
Net activity
-363,264
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-04-20 | Daniels Eric Joseph | Officer | A-Award | A | Stock Option (Right to Buy) | 20,000 | 7.30 | 146.0K | 20,000 | D | ↗ |
| 2026-04-01 | Sims Andrew John Hugh MacIntyre | Officer | M-Exempt | D | Restricted Stock Units | 38,323 | 0.00 | — | 694,451 | D | ↗ |
| 2026-04-01 | HEDRICK MARC H | Director / Officer | M-Exempt | D | Restricted Stock Units | 159,681 | 0.00 | — | 3,856,707 | D | ↗ |
| 2026-03-20 | ANDREWS RONALD ASBURY | Director | — | — | Common Stock | 0 | 0.00 | — | 0 | D | ↗ |
| 2026-02-25 | Sims Andrew John Hugh MacIntyre | Officer | A-Award | A | Stock Option (Right to Buy) | 349,541 | 0.28 | 97.9K | 349,541 | D | ↗ |
| 2026-02-25 | HEDRICK MARC H | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 2,419,582 | 0.28 | 677.5K | 2,419,582 | D | ↗ |
| 2026-01-01 | Sims Andrew John Hugh MacIntyre | Officer | M-Exempt | D | Restricted Stock Units | 38,323 | 0.00 | — | 383,232 | D | ↗ |
| 2026-01-01 | HEDRICK MARC H | Director / Officer | M-Exempt | D | Restricted Stock Units | 159,681 | 0.00 | — | 1,596,806 | D | ↗ |
| 2025-11-04 | Sims Andrew John Hugh MacIntyre | Officer | P-Purchase | A | Common Stock | 20,000 | 0.51 | 10.2K | 68,138 | D | ↗ |
| 2025-10-01 | Sims Andrew John Hugh MacIntyre | Officer | M-Exempt | D | Restricted Stock Units | 38,323 | 0.00 | — | 421,555 | D | ↗ |
| 2025-10-01 | HEDRICK MARC H | Director / Officer | M-Exempt | D | Restricted Stock Units | 159,681 | 0.00 | — | 1,756,487 | D | ↗ |
| 2025-08-22 | Lenk Robert P | Director | P-Purchase | A | Common Stock | 110,000 | 0.49 | 53.8K | 139,327 | D | ↗ |
| 2025-08-13 | van Es-Johansson An | Director | A-Award | A | Stock Option (Right to Buy) | 297,794 | 0.57 | 171.1K | 297,794 | D | ↗ |
| 2025-08-13 | Sims Andrew John Hugh MacIntyre | Officer | A-Award | A | Restricted Stock Units | 459,878 | 0.00 | — | 459,878 | D | ↗ |
| 2025-08-13 | Lenk Robert P | Director | A-Award | A | Stock Option (Right to Buy) | 297,794 | 0.57 | 171.1K | 297,794 | D | ↗ |
| 2025-08-13 | Hawkins Richard J | Director | A-Award | A | Stock Option (Right to Buy) | 397,794 | 0.57 | 228.5K | 397,794 | D | ↗ |
| 2025-08-13 | HEDRICK MARC H | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 5,748,506 | 0.57 | 3.30M | 5,748,506 | D | ↗ |
| 2025-08-13 | Guse Kyle | Director | A-Award | A | Stock Option (Right to Buy) | 40,000 | 0.57 | 23.0K | 40,000 | D | ↗ |
| 2025-08-13 | Clowes Howard | Director | A-Award | A | Stock Option (Right to Buy) | 297,794 | 0.57 | 171.1K | 297,794 | D | ↗ |
| 2025-04-18 | Guse Kyle | Director | — | — | Common Stock | 0 | 0.00 | — | 0 | D | ↗ |
| 2025-02-18 | van Es-Johansson An | Director | A-Award | A | Stock Option (Right to Buy) | 40,122 | 1.18 | 47.3K | 40,122 | D | ↗ |
| 2025-02-18 | Sims Andrew John Hugh MacIntyre | Officer | A-Award | A | Stock Option (Right to Buy) | 60,020 | 1.18 | 70.8K | 60,020 | D | ↗ |
| 2025-02-18 | Petersen Greg | Director | A-Award | A | Stock Option (Right to Buy) | 40,122 | 1.18 | 47.3K | 40,122 | D | ↗ |
| 2025-02-18 | Lenk Robert P | Director | A-Award | A | Stock Option (Right to Buy) | 40,122 | 1.18 | 47.3K | 40,122 | D | ↗ |
| 2025-02-18 | Hawkins Richard J | Director | A-Award | A | Stock Option (Right to Buy) | 40,122 | 1.18 | 47.3K | 40,122 | D | ↗ |
| 2025-02-18 | HEDRICK MARC H | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 400,489 | 1.18 | 472.6K | 400,489 | D | ↗ |
| 2025-02-18 | Clowes Howard | Director | A-Award | A | Stock Option (Right to Buy) | 40,122 | 1.18 | 47.3K | 40,122 | D | ↗ |
| 2024-09-13 | Hawkins Richard J | Director | P-Purchase | A | Common Stock | 4,000 | 1.50 | 6.0K | 15,188 | — | ↗ |
| 2024-09-12 | Hawkins Richard J | Director | P-Purchase | A | Common Stock | 6,285 | 1.35 | 8.5K | 11,188 | — | ↗ |
| 2024-09-11 | van Es-Johansson An | Director | A-Award | A | Stock Option (Right to Buy) | 3,650 | 1.26 | 4.6K | 3,650 | — | ↗ |
| 2024-09-11 | Sims Andrew John Hugh MacIntyre | Officer | A-Award | A | Stock Option (Right to Buy) | 46,074 | 1.26 | 58.1K | 46,074 | — | ↗ |
| 2024-09-11 | Petersen Greg | Director | A-Award | A | Stock Option (Right to Buy) | 3,650 | 1.26 | 4.6K | 3,650 | — | ↗ |
| 2024-09-11 | Lenk Robert P | Director | A-Award | A | Stock Option (Right to Buy) | 3,650 | 1.26 | 4.6K | 3,650 | — | ↗ |
| 2024-09-11 | Hawkins Richard J | Director | A-Award | A | Stock Option (Right to Buy) | 3,650 | 1.26 | 4.6K | 3,650 | — | ↗ |
| 2024-09-11 | HEDRICK MARC H | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 197,595 | 1.26 | 249.0K | 197,595 | — | ↗ |
| 2024-09-11 | Clowes Howard | Director | A-Award | A | Stock Option (Right to Buy) | 3,650 | 1.26 | 4.6K | 3,650 | — | ↗ |
| 2024-09-10 | Sims Andrew John Hugh MacIntyre | Officer | P-Purchase | A | Common Stock | 4,098 | 1.27 | 5.2K | 9,815 | — | ↗ |
| 2024-09-10 | HEDRICK MARC H | Director / Officer | P-Purchase | A | Common Stock | 8,000 | 1.23 | 9.8K | 20,425 | — | ↗ |
| 2024-05-08 | Sims Andrew John Hugh MacIntyre | Officer | P-Purchase | A | Common Stock | 4,902 | 2.04 | 10.0K | 5,717 | — | ↗ |
| 2024-05-08 | Petersen Greg | Director | A-Award | A | Warrants (Right to buy) | 24,510 | 1.79 | 43.9K | 24,510 | — | ↗ |
| 2024-05-08 | Lenk Robert P | Director | P-Purchase | A | Common Stock | 4,167 | 2.04 | 8.5K | 29,327 | — | ↗ |
| 2024-05-08 | Hawkins Richard J | Director | P-Purchase | A | Common Stock | 4,902 | 2.04 | 10.0K | 4,903 | — | ↗ |
| 2024-05-08 | HEDRICK MARC H | Director / Officer | P-Purchase | A | Common Stock | 12,255 | 2.04 | 25.0K | 12,425 | — | ↗ |
| 2024-05-08 | Clowes Howard | Director | A-Award | A | Warrants (Right to buy) | 19,608 | 1.79 | 35.1K | 19,608 | — | ↗ |
| 2024-02-22 | van Es-Johansson An | Director | A-Award | A | Stock Option (Right to Buy) | 2,250 | 2.03 | 4.6K | 2,250 | — | ↗ |
| 2024-02-22 | Sims Andrew John Hugh MacIntyre | Officer | A-Award | A | Stock Option (Right to Buy) | 18,933 | 2.03 | 38.4K | 18,933 | — | ↗ |
| 2024-02-22 | Petersen Greg | Director | A-Award | A | Stock Option (Right to Buy) | 2,250 | 2.03 | 4.6K | 2,250 | — | ↗ |
| 2024-02-22 | Lenk Robert P | Director | A-Award | A | Stock Option (Right to Buy) | 2,250 | 2.03 | 4.6K | 2,250 | — | ↗ |
| 2024-02-22 | LaFrance Norman D. | Officer | A-Award | A | Stock Option (Right to Buy) | 24,073 | 2.03 | 48.9K | 24,073 | — | ↗ |
| 2024-02-22 | Hawkins Richard J | Director | A-Award | A | Stock Option (Right to Buy) | 2,250 | 2.03 | 4.6K | 2,250 | — | ↗ |
| 2024-02-22 | HEDRICK MARC H | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 94,012 | 2.03 | 190.8K | 94,012 | — | ↗ |
| 2024-02-22 | Clowes Howard | Director | A-Award | A | Stock Option (Right to Buy) | 2,250 | 2.03 | 4.6K | 2,250 | — | ↗ |
| 2023-11-20 | HEDRICK MARC H | Director / Officer | S-Sale | D | Common Stock | 2,068 | 1.96 | 4.1K | 170 | — | ↗ |
| 2023-11-16 | Lenk Robert P | Director | P-Purchase | A | Common Stock | 1,000 | 1.95 | 2.0K | 25,160 | — | ↗ |
| 2023-11-15 | Lenk Robert P | Director | P-Purchase | A | Common Stock | 1,000 | 1.77 | 1.8K | 24,160 | — | ↗ |
| 2023-11-13 | Lenk Robert P | Director | P-Purchase | A | Common Stock | 4,000 | 1.43 | 5.7K | 23,160 | — | ↗ |
| 2023-11-10 | Lenk Robert P | Director | P-Purchase | A | Common Stock | 2,000 | 1.45 | 2.9K | 19,160 | — | ↗ |
| 2023-11-09 | Lenk Robert P | Director | P-Purchase | A | Common Stock | 4,199 | 1.59 | 6.7K | 17,160 | — | ↗ |
| 2023-11-08 | Lenk Robert P | Director | P-Purchase | A | Common Stock | 5,000 | 1.65 | 8.3K | 12,961 | — | ↗ |
| 2023-11-07 | Lenk Robert P | Director | P-Purchase | A | Common Stock | 6,000 | 1.64 | 9.8K | 7,961 | — | ↗ |
| 2023-11-06 | Lenk Robert P | Director | P-Purchase | A | Common Stock | 1,395 | 1.50 | 2.1K | 1,961 | — | ↗ |
| 2023-09-13 | Clowes Howard | Director | P-Purchase | A | Common Stock | 6,993 | 1.43 | 10.0K | 11,693 | — | ↗ |
| 2023-09-11 | Petersen Greg | Director | P-Purchase | A | Common Stock | 20,000 | 1.70 | 34.1K | 24,166 | — | ↗ |
| 2023-06-06 | Clowes Howard | Director | P-Purchase | A | Common Stock | 1,000 | 3.98 | 4.0K | 4,700 | — | ↗ |
| 2023-05-03 | Clowes Howard | Director | P-Purchase | A | Common Stock | 2,500 | 3.64 | 9.1K | 3,700 | — | ↗ |
| 2023-03-03 | Hawkins Richard J | Director | P-Purchase | A | Series F Preferred Stock | 1 | 1,000.00 | 1.0K | 1 | — | ↗ |
| 2023-02-15 | van Es-Johansson An | Director | A-Award | A | Stock Option (Right to Buy) | 20,182 | 0.39 | 7.9K | 20,182 | — | ↗ |
| 2023-02-15 | Sims Andrew John Hugh MacIntyre | Officer | A-Award | A | Stock Option (Right to Buy) | 104,404 | 0.39 | 40.7K | 104,404 | — | ↗ |
| 2023-02-15 | Petersen Greg | Director | A-Award | A | Stock Option (Right to Buy) | 20,182 | 0.39 | 7.9K | 20,182 | — | ↗ |
| 2023-02-15 | LaFrance Norman D. | Officer | A-Award | A | Stock Option (Right to Buy) | 74,981 | 0.39 | 29.2K | 74,981 | — | ↗ |
| 2023-02-15 | Hawkins Richard J | Director | A-Award | A | Stock Option (Right to Buy) | 20,182 | 0.39 | 7.9K | 20,182 | — | ↗ |
| 2023-02-15 | HEDRICK MARC H | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 483,824 | 0.39 | 188.7K | 483,824 | — | ↗ |
| 2023-02-15 | Clowes Howard | Director | A-Award | A | Stock Option (Right to Buy) | 20,182 | 0.39 | 7.9K | 20,182 | — | ↗ |
| 2022-12-30 | Lenk Robert P | Director | S-Sale | D | Common Stock | 1,500 | 0.31 | 472.05 | 8,500 | — | ↗ |
| 2022-06-15 | HEDRICK MARC H | Officer | P-Purchase | A | Common Stock | 5,000 | 0.65 | 3.2K | 33,580 | — | ↗ |
| 2022-06-02 | Clowes Howard | Director | P-Purchase | A | Common Stock | 15,000 | 0.57 | 8.6K | 18,000 | — | ↗ |
| 2022-05-17 | Petersen Greg | Director | P-Purchase | A | Common Stock | 30,000 | 0.55 | 16.5K | 62,500 | — | ↗ |
| 2022-04-27 | HEDRICK MARC H | Officer | P-Purchase | A | Common Stock | 2,500 | 0.68 | 1.7K | 28,580 | — | ↗ |
| 2022-04-26 | Sims Andrew John Hugh MacIntyre | Officer | P-Purchase | A | Common Stock | 3,000 | 0.67 | 2.0K | 12,230 | — | ↗ |
| 2022-04-26 | HEDRICK MARC H | Director / Officer | P-Purchase | A | Common Stock | 2,500 | 0.68 | 1.7K | 28,580 | — | ↗ |
| 2022-03-01 | Sims Andrew John Hugh MacIntyre | Officer | P-Purchase | A | Common Stock | 2,000 | 1.10 | 2.2K | 9,230 | — | ↗ |
| 2021-11-11 | LaFrance Norman D. | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2021-11-02 | Sims Andrew John Hugh MacIntyre | Officer | P-Purchase | A | Common Stock | 1,000 | 1.86 | 1.9K | 7,230 | — | ↗ |
| 2021-11-01 | LaFrance Norman D. | Officer | A-Award | A | Stock Option (right to buy shares of common stock) | 120,000 | 120,000.00 | 14.40B | 120,000 | — | ↗ |
| 2021-10-27 | Petersen Greg | Director | P-Purchase | A | Common Stock | 12,500 | 1.72 | 21.5K | 32,500 | — | ↗ |
| 2021-10-26 | Sims Andrew John Hugh MacIntyre | Officer | P-Purchase | A | Common Stock | 2,000 | 1.67 | 3.3K | 6,230 | — | ↗ |
| 2021-10-26 | HEDRICK MARC H | Director / Officer | P-Purchase | A | Common Stock | 2,500 | 1.66 | 4.1K | 21,080 | — | ↗ |
| 2021-09-13 | Lenk Robert P | Director | P-Purchase | A | Common Stock | 7,000 | 1.86 | 13.0K | 10,000 | — | ↗ |
| 2021-07-28 | Sims Andrew John Hugh MacIntyre | Officer | P-Purchase | A | Common Stock | 2,244 | 1.91 | 4.3K | 4,230 | — | ↗ |
| 2021-07-27 | Sims Andrew John Hugh MacIntyre | Officer | P-Purchase | A | Common Stock | 1,986 | 2.05 | 4.1K | 1,986 | — | ↗ |
| 2021-06-11 | Hawkins Richard J | Director | A-Award | A | Stock Option (Right to Buy) | 40,000 | 2.88 | 115.2K | 40,000 | — | ↗ |
| 2021-05-25 | van Es-Johansson An | Director | A-Award | A | Stock Option (Right to Buy) | 6,336 | 2.25 | 14.3K | 6,336 | — | ↗ |
| 2021-05-25 | Sims Andrew John Hugh MacIntyre | Officer | A-Award | A | Stock Option (right to buy) | 100,197 | 2.25 | 225.4K | 100,197 | — | ↗ |
| 2021-05-25 | Petersen Greg | Director | A-Award | A | Stock Option (Right to Buy) | 6,336 | 2.25 | 14.3K | 6,336 | — | ↗ |
| 2021-05-25 | Lenk Robert P | Director | A-Award | A | Stock Option (Right to Buy) | 6,336 | 2.25 | 14.3K | 6,336 | — | ↗ |
| 2021-05-25 | HEDRICK MARC H | Director / Officer | A-Award | A | Stock Option (right to buy) | 200,771 | 2.25 | 451.7K | 200,771 | — | ↗ |
| 2021-05-25 | Clowes Howard | Director | A-Award | A | Stock Option (Right to Buy) | 6,336 | 2.25 | 14.3K | 6,336 | — | ↗ |
| 2021-04-30 | HEDRICK MARC H | Director / Officer | P-Purchase | A | Common Stock | 2,183 | 2.28 | 5.0K | 18,580 | — | ↗ |
| 2021-03-04 | HEDRICK MARC H | Director / Officer | P-Purchase | A | Common Stock | 2,500 | 2.50 | 6.3K | 16,397 | — | ↗ |
| 2021-03-03 | Clowes Howard | Director | P-Purchase | A | Common Stock | 3,000 | 2.42 | 7.3K | 3,000 | — | ↗ |
| 2021-02-16 | Sims Andrew John Hugh MacIntyre | Officer | A-Award | A | Stock Option (right to buy) | 66,625 | 3.64 | 242.5K | 66,625 | — | ↗ |
| 2021-02-16 | HEDRICK MARC H | Director / Officer | A-Award | A | Stock Option (right to buy) | 88,314 | 3.64 | 321.5K | 88,314 | — | ↗ |
| 2020-12-10 | HEDRICK MARC H | Director / Officer | P-Purchase | A | Common Stock | 2,500 | 1.99 | 5.0K | 13,867 | — | ↗ |
| 2020-11-30 | HEDRICK MARC H | Officer | P-Purchase | A | Common Stock | 2,200 | 2.14 | 4.7K | 11,367 | — | ↗ |
| 2020-08-25 | Lenk Robert P | Director | P-Purchase | A | Common Stock | 3,000 | 2.49 | 7.5K | 3,000 | — | ↗ |
| 2020-08-13 | Petersen Greg | Director | P-Purchase | A | Common Stock | 10,000 | 2.80 | 28.0K | 20,000 | — | ↗ |
| 2020-08-12 | Petersen Greg | Director | P-Purchase | A | Common Stock | 10,000 | 2.52 | 25.2K | 10,000 | — | ↗ |
| 2020-08-12 | HEDRICK MARC H | Officer | P-Purchase | A | Common Stock | 4,000 | 2.58 | 10.3K | 9,167 | — | ↗ |
| 2020-06-25 | van Es-Johansson An | Director | A-Award | A | Stock Option (Right to Buy) | 34,000 | 2.10 | 71.4K | 34,000 | — | ↗ |
| 2020-06-25 | Lenk Robert P | Director | A-Award | A | Stock Option (Right to Buy) | 40,000 | 2.10 | 84.0K | 40,000 | — | ↗ |
| 2020-06-25 | Hawkins Richard J | Director | A-Award | A | Stock Option (Right to Buy) | 40,000 | 2.10 | 84.0K | 40,000 | — | ↗ |
| 2020-06-25 | HEDRICK MARC H | Officer | A-Award | A | Stock Option (Right to Buy) | 140,000 | 2.10 | 294.0K | 140,000 | — | ↗ |
| 2020-06-25 | Clowes Howard | Director | A-Award | A | Stock Option (Right to Buy) | 40,000 | 2.10 | 84.0K | 40,000 | — | ↗ |
| 2020-06-22 | HEDRICK MARC H | Officer | P-Purchase | A | Common Stock | 5,000 | 2.10 | 10.5K | 5,167 | — | ↗ |
| 2020-04-01 | Lenk Robert P | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2020-04-01 | Clowes Howard | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2020-02-14 | Petersen Greg | Director | A-Award | A | Stock Option (right to buy) | 40,000 | 2.16 | 86.4K | 40,000 | — | ↗ |
| 2020-02-06 | Sims Andrew John Hugh MacIntyre | Officer | A-Award | A | Stock Option (right to buy) | 40,000 | 2.23 | 89.2K | 40,000 | — | ↗ |
| 2020-02-05 | Sims Andrew John Hugh MacIntyre | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2020-01-09 | van Es-Johansson An | Director | A-Award | A | Stock Option (right to buy) | 6,000 | 2.57 | 15.4K | 6,000 | — | ↗ |
| 2020-01-01 | van Es-Johansson An | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2018-07-25 | Hawkins Richard J | Director | X-InTheMoney | A | Warrants (Right to Buy) | 10,500 | 0.80 | 8.4K | 10,500 | — | ↗ |
| 2018-07-25 | HEDRICK MARC H | Officer | X-InTheMoney | D | Subscription Rights (Right to Buy) | 35 | 1,000.00 | 35.0K | 0 | — | ↗ |
| 2018-07-25 | Girao Tiago | Officer | X-InTheMoney | D | Subscription Rights (Right to Buy) | 1 | 1,000.00 | 1.0K | 0 | — | ↗ |
| 2018-02-14 | PostFinance AG | 10% Owner | S-Sale | D | Common Stock | 473,831 | 0.34 | 161.0K | 4,543,086 | — | ↗ |
| 2018-02-13 | PostFinance AG | 10% Owner | S-Sale | D | Common Stock | 101,710 | 0.31 | 31.7K | 5,016,917 | — | ↗ |
| 2018-02-12 | PostFinance AG | 10% Owner | S-Sale | D | Common Stock | 185,272 | 0.31 | 58.3K | 5,118,627 | — | ↗ |
| 2018-02-09 | PostFinance AG | 10% Owner | S-Sale | D | Common Stock | 7,552 | 0.34 | 2.6K | 5,303,899 | — | ↗ |
| 2018-02-08 | PostFinance AG | 10% Owner | S-Sale | D | Common Stock | 228,603 | 0.34 | 78.4K | 5,311,451 | — | ↗ |
| 2018-01-25 | PostFinance AG | 10% Owner | — | D | Common Stock | 0 | 0.00 | — | 5,540,054 | — | ↗ |
| 2018-01-11 | Swissquote Bank SA | 10% Owner | S-Sale | D | Common Stock | 20,000 | 0.34 | 6.8K | 5,360,859 | — | ↗ |
| 2018-01-10 | Swissquote Bank SA | 10% Owner | S-Sale | D | Common Stock | 15,796 | 0.38 | 6.0K | 5,400,859 | — | ↗ |
| 2018-01-09 | Swissquote Bank SA | 10% Owner | S-Sale | D | Common Stock | 20,000 | 0.37 | 7.4K | 5,496,655 | — | ↗ |
| 2017-12-29 | Swissquote Bank SA | 10% Owner | — | D | Common Stock | 0 | 0.00 | — | 5,540,055 | — | ↗ |
| 2017-11-28 | RICKEY DAVID | Director | X-InTheMoney | D | Subscription Rights (Right to Buy) | 6 | 1,000.00 | 6.0K | 0 | — | ↗ |
| 2017-11-28 | Naughton Gail K | Director | X-InTheMoney | A | Series B Preferred Stock | 1 | 0.33 | 0.33 | 1 | — | ↗ |
| 2017-11-28 | LYONS GARY A | Director | X-InTheMoney | D | Subscription Rights (Right to Buy) | 1 | 1,000.00 | 1.0K | 0 | — | ↗ |
| 2017-11-28 | Hawkins Richard J | Director | X-InTheMoney | D | Subscription Rights (Right to Buy) | 3 | 1,000.00 | 3.0K | 0 | — | ↗ |
| 2017-11-28 | HEDRICK MARC H | Director / Officer | X-InTheMoney | A | Series B Preferred Stock | 9 | 0.33 | 3.00 | 9 | — | ↗ |
| 2017-11-28 | HARRIS JOHN DAVID | Officer | X-InTheMoney | A | Warrants (Right to Buy) | 1,800 | 0.33 | 599.94 | 1,800 | — | ↗ |
| 2017-11-28 | Girao Tiago | Officer | X-InTheMoney | A | Warrants (Right to Buy) | 1,800 | 0.33 | 599.94 | 1,800 | — | ↗ |
| 2017-05-22 | LAPOINTE ANTHONY GREGG | Director | A-Award | A | Non-Qualified Stock Option (right to buy) | 50,000 | 1.60 | 80.0K | 50,000 | — | ↗ |
| 2017-03-31 | LAPOINTE ANTHONY GREGG | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2017-03-08 | Marino Mark | Officer | A-Award | A | Incentive Stock Option (right to buy) | 31,100 | 1.55 | 48.2K | 31,100 | — | ↗ |
| 2017-03-08 | HEDRICK MARC H | Director / Officer | A-Award | A | Incentive Stock Option (right to buy) | 96,350 | 1.55 | 149.3K | 96,350 | — | ↗ |
| 2017-03-08 | HAYDEN JEREMY B. | Officer | A-Award | A | Incentive Stock Option (right to buy) | 31,100 | 1.55 | 48.2K | 31,100 | — | ↗ |
| 2017-03-08 | HARRIS JOHN DAVID | Officer | A-Award | A | Incentive Stock Option (right to buy) | 31,100 | 1.55 | 48.2K | 31,100 | — | ↗ |
| 2017-03-08 | Girao Tiago | Officer | A-Award | A | Incentive Stock Option (right to buy) | 31,100 | 1.55 | 48.2K | 31,100 | — | ↗ |
| 2017-01-26 | RICKEY DAVID | Director | A-Award | A | Non-Qualified Stock Option (right to buy)_ | 25,000 | 1.56 | 39.0K | 25,000 | — | ↗ |
| 2017-01-26 | Naughton Gail K | Director | A-Award | A | Non-Qualified Stock Option (right to buy) | 25,000 | 1.56 | 39.0K | 25,000 | — | ↗ |
| 2017-01-26 | MARTELL RON | Director | A-Award | A | Non-Qualified Stock Option (right to buy) | 50,000 | 1.56 | 78.0K | 50,000 | — | ↗ |
| 2017-01-26 | LYONS GARY A | Director | A-Award | A | Non-Qualified Stock Option (right to buy) | 25,000 | 1.56 | 39.0K | 25,000 | — | ↗ |
| 2017-01-26 | Hawkins Richard J | Director | A-Award | A | Non-Qualified Stock Option (right to buy) | 25,000 | 1.56 | 39.0K | 25,000 | — | ↗ |
| 2017-01-26 | HAWRAN PAUL W | Director | A-Award | A | Non-Qualified Stock Option (right to buy) | 25,000 | 1.56 | 39.0K | 25,000 | — | ↗ |
| 2016-12-27 | MARTELL RON | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2016-08-19 | Marino Mark | Officer | — | D | Stock Option (Right to Buy) | 33,333 | 2.18 | 72.7K | 0 | — | ↗ |
| 2016-08-10 | HARRIS JOHN DAVID | Officer | P-Purchase | A | Common Stock | 2,500 | 2.03 | 5.1K | 7,000 | — | ↗ |
| 2016-06-15 | RICKEY DAVID | Director | X-InTheMoney | A | Warrants (Right to Buy) | 3,000 | 3.06 | 9.2K | 3,000 | — | ↗ |
| 2016-06-15 | LYONS GARY A | Director | X-InTheMoney | D | Subscription Rights (Right to Buy) | 1,900 | 2.55 | 4.8K | 0 | — | ↗ |
| 2016-06-15 | KESTEN STEVEN | Officer | X-InTheMoney | D | Subscription Rights (Right to Buy) | 200 | 2.55 | 510.00 | 0 | — | ↗ |
| 2016-06-15 | Hawkins Richard J | Director | X-InTheMoney | D | Subscription Rights (Right to Buy) | 3,356 | 2.55 | 8.6K | 0 | — | ↗ |
| 2016-06-15 | HEDRICK MARC H | Director / Officer | X-InTheMoney | D | Subscription Rights (Right to Buy) | 41,305 | 2.55 | 105.3K | 0 | — | ↗ |
| 2016-06-15 | HAYDEN JEREMY B. | Officer | X-InTheMoney | A | Warrants (Right to Buy) | 948 | 3.06 | 2.9K | 948 | — | ↗ |
| 2016-06-15 | HARRIS JOHN DAVID | Officer | X-InTheMoney | D | Subscription Rights (Right to Buy) | 2,500 | 2.55 | 6.4K | 0 | — | ↗ |
| 2016-06-15 | Girao Tiago | Officer | X-InTheMoney | A | Common Stock | 5,667 | 2.55 | 14.5K | 14,084 | — | ↗ |
| 2016-06-14 | RICKEY DAVID | Director | P-Purchase | A | Common Stock | 5,000 | 2.10 | 10.5K | 55,226 | — | ↗ |
| 2016-06-14 | Naughton Gail K | Director | P-Purchase | A | Common Stock | 1,000 | 2.10 | 2.1K | 2,400 | — | ↗ |
| 2016-05-13 | HARRIS JOHN DAVID | Officer | P-Purchase | A | Common Stock | 2,000 | 2.71 | 5.4K | 2,000 | — | ↗ |
| 2016-03-09 | RICKEY DAVID | Director | P-Purchase | A | Common Stock | 100,000 | 0.19 | 18.9K | 753,385 | — | ↗ |
| 2016-01-28 | KESTEN STEVEN | Officer | A-Award | A | Common Stock | 47,000 | 0.00 | — | 49,201 | — | ↗ |
| 2016-01-28 | HEDRICK MARC H | Director / Officer | A-Award | A | Common Stock | 70,500 | 0.00 | — | 575,111 | — | ↗ |
| 2016-01-28 | Girao Tiago | Officer | A-Award | A | Common Stock | 35,250 | 0.00 | — | 126,250 | — | ↗ |
| 2016-01-04 | Thompson Tommy G | Director | A-Award | A | Incentive Stock Option (Right to Buy) | 53,820 | 0.00 | — | 136,950 | — | ↗ |
| 2016-01-04 | RICKEY DAVID | Director | A-Award | A | Incentive Stock Option (Right to Buy) | 53,820 | 0.00 | — | 245,950 | — | ↗ |
| 2016-01-04 | Naughton Gail K | Director | A-Award | A | Incentive Stock Option (Right to Buy) | 53,820 | 0.00 | — | 99,820 | — | ↗ |
| 2016-01-04 | LYONS GARY A | Director | A-Award | A | Incentive Stock Option (Right to Buy) | 53,820 | 0.00 | — | 99,820 | — | ↗ |
| 2016-01-04 | KESTEN STEVEN | Officer | A-Award | A | Employee Stock Option | 699,660 | 0.00 | — | 1,240,660 | — | ↗ |
| 2016-01-04 | Hawkins Richard J | Director | A-Award | A | Incentive Stock Option (Right to Buy) | 53,820 | 0.00 | — | 220,950 | — | ↗ |
| 2016-01-04 | HEDRICK MARC H | Director / Officer | A-Award | A | Employee Stock Option | 834,210 | 0.00 | — | 2,269,210 | — | ↗ |
| 2016-01-04 | HAYDEN JEREMY B. | Officer | A-Award | A | Employee Stock Option | 255,645 | 0.00 | — | 455,645 | — | ↗ |
| 2016-01-04 | HAWRAN PAUL W | Director | A-Award | A | Incentive Stock Option (Right to Buy) | 53,820 | 0.00 | — | 245,950 | — | ↗ |
| 2016-01-04 | HARRIS JOHN DAVID | Officer | A-Award | A | Employee Stock Option | 349,830 | 0.00 | — | 684,830 | — | ↗ |
| 2016-01-04 | Girao Tiago | Officer | A-Award | A | Employee Stock Option | 349,830 | 0.00 | — | 619,830 | — | ↗ |
| 2015-11-11 | HARRIS JOHN DAVID | Officer | A-Award | A | Stock Option (Right to Buy) | 335,000 | 0.37 | 124.0K | 335,000 | — | ↗ |
| 2015-10-01 | HARRIS JOHN DAVID | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2015-09-03 | Thompson Tommy G | Director | P-Purchase | A | Common Stock | 25,449 | 0.37 | 9.5K | 83,600 | — | ↗ |
| 2015-09-02 | HAYDEN JEREMY B. | Officer | P-Purchase | A | Common Stock | 8,200 | 0.36 | 2.9K | 26,200 | — | ↗ |
| 2015-08-28 | RICKEY DAVID | Director | P-Purchase | A | Common Stock | 21,000 | 0.31 | 6.6K | 653,385 | — | ↗ |
| 2015-08-28 | HEDRICK MARC H | Director / Officer | P-Purchase | A | Common Stock | 1,200 | 0.31 | 372.00 | 44,800 | — | ↗ |
| 2015-08-27 | RICKEY DAVID | Director | P-Purchase | A | Common Stock | 50,000 | 0.30 | 15.0K | 632,385 | — | ↗ |
| 2015-08-27 | HEDRICK MARC H | Director / Officer | P-Purchase | A | Common Stock | 10,000 | 0.31 | 3.1K | 43,600 | — | ↗ |
| 2015-08-26 | RICKEY DAVID | Director | P-Purchase | A | Common Stock | 25,000 | 0.33 | 8.2K | 582,385 | — | ↗ |
| 2015-08-21 | RICKEY DAVID | Director | P-Purchase | A | Common Stock | 50,000 | 0.38 | 18.8K | 557,385 | — | ↗ |
| 2015-08-21 | HEDRICK MARC H | Director / Officer | P-Purchase | A | Common Stock | 5,000 | 0.35 | 1.8K | 33,600 | — | ↗ |
| 2015-08-20 | HEDRICK MARC H | Director / Officer | P-Purchase | A | Common Stock | 9,700 | 0.40 | 3.9K | 23,600 | — | ↗ |
| 2015-08-19 | RICKEY DAVID | Director | P-Purchase | A | Common Stock | 48,600 | 0.39 | 19.1K | 507,385 | — | ↗ |
| 2015-08-19 | KESTEN STEVEN | Officer | P-Purchase | A | Common Stock | 6,000 | 0.39 | 2.3K | 6,000 | — | ↗ |
| 2015-08-19 | HAYDEN JEREMY B. | Officer | P-Purchase | A | Common Stock | 18,000 | 0.39 | 7.1K | 18,000 | — | ↗ |
| 2015-08-18 | RICKEY DAVID | Director | P-Purchase | A | Common Stock | 51,400 | 0.39 | 20.2K | 458,785 | — | ↗ |
| 2015-08-18 | HEDRICK MARC H | Director / Officer | P-Purchase | A | Common Stock | 100 | 0.39 | 38.99 | 3,700 | — | ↗ |
Executive team
Top executives
EBIT / Employee
-7.3K
Shares Outstanding
2.42M
Executive compensation
Executive compensation (annual)
| # | Year | Executive | Salary | Bonus | Stock award | Option award | Incentive | Other | Total | % Stock- based |
Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2022 | Marc H. Hedrick, M.D. President and Chief Executive Officer | 535.0K | — | — | — | 361.9K | 57.7K | 954.7K | 0.00% | ↗ |
| 2 | 2022 | Norman LaFrance, M.D. Chief Medical Officer | 440.0K | — | — | — | 152.5K | 45.4K | 637.8K | 0.00% | ↗ |
| 3 | 2022 | Andrew Sims Chief Financial Officer | 305.0K | — | — | — | 125.2K | 16.0K | 446.2K | 0.00% | ↗ |
| 4 | 2021 | Marc H. Hedrick, M.D. President and Chief Executive Officer | 510.0K | — | — | 773.2K | 364.7K | 19.4K | 1.67M | 46.37% | ↗ |
| 5 | 2021 | Andrew Sims Chief Financial Officer | 260.0K | — | — | 468.0K | 108.1K | 9.1K | 845.1K | 55.37% | ↗ |
| 6 | 2021 | Norman LaFrance, M.D. Chief Medical Officer | 60.1K | — | — | 205.2K | 27.4K | — | 292.7K | 70.10% | ↗ |
| 7 | 2020 | Marc H. Hedrick, M.D. President and Chief Executive Officer | 510.0K | — | — | — | 322.6K | 5.9K | 1.13M | 0.00% | ↗ |
| 8 | 2020 | Marc H. Hedrick, M.D. President and Chief Executive Officer | 510.0K | — | — | — | 322.6K | 5.9K | 838.4K | 0.00% | ↗ |
| 9 | 2020 | Andrew Sims Chief Financial Officer | 235.5K | — | — | — | 86.8K | 1.5K | 413.0K | 0.00% | ↗ |
| 10 | 2019 | Marc H. Hedrick, M.D., President and Chief Executive Officer | 510.0K | — | — | — | 350.6K | 6.8K | 867.4K | 0.00% | ↗ |
| 11 | 2019 | Marc H. Hedrick, M.D. President and Chief Executive Officer | 510.0K | — | — | — | 350.6K | 6.8K | 867.4K | 0.00% | ↗ |
| 12 | 2019 | Tiago M. Girão , Former Chief Financial Officer and SVP of Operations | 108.6K | — | — | — | — | 582.00 | 109.2K | 0.00% | ↗ |
| 13 | 2018 | Marc H. Hedrick, M.D., President and Chief Executive Officer | 510.0K | — | — | — | 98.2K | 6.8K | 615.0K | 0.00% | ↗ |
| 14 | 2018 | Marc H. Hedrick, M.D., President and Chief Executive Officer | 510.0K | — | — | — | 98.2K | 6.8K | 615.0K | 0.00% | ↗ |
| 15 | 2018 | Tiago M. Girão , Former Chief Financial Officer and SVP of Operations | 309.0K | — | — | — | 43.3K | 2.3K | 354.6K | 0.00% | ↗ |
| 16 | 2018 | Tiago M. Girao, Former CFO and SVP of Operations | 309.0K | — | — | — | 43.3K | 2.3K | 354.6K | 0.00% | ↗ |
| 17 | 2018 | John D. Harris, Former VP and GM of Cell Therapy | 123.9K | — | — | — | — | 1.4K | 125.3K | 0.00% | ↗ |
| 18 | 2017 | Marc H. Hedrick, M.D., President and Chief Executive Officer | 500.0K | — | — | 116.2K | 140.3K | 89.6K | 846.0K | 13.73% | ↗ |
| 19 | 2017 | John D. Harris, Former VP and GM of Cell Therapy | 358.8K | — | — | 48.2K | 64.9K | 94.0K | 565.8K | 8.52% | ↗ |
| 20 | 2017 | John Harris, VP and General Manager of Cell Therapy | 358.8K | — | — | 48.2K | 64.9K | 94.0K | 565.8K | 8.52% | ↗ |
| 21 | 2017 | Tiago M. Girao, VP of Finance, Chief Financial Officer and Chief Accounting Officer | 307.5K | — | — | 48.2K | 72.6K | 46.4K | 474.7K | 10.16% | ↗ |
| 22 | 2017 | Tiago M. Girao, Former CFO and SVP of Operations | 307.5K | — | — | 48.2K | 72.6K | 46.4K | 474.7K | 10.16% | ↗ |
| 23 | 2016 | Marc H. Hedrick, M.D., President and Chief Executive Officer | 450.0K | — | — | 156.3K | 146.3K | — | 752.5K | 20.77% | ↗ |
| 24 | 2016 | John D. Harris, VP and General Manager of Cell Therapy | 361.8K | — | — | 65.5K | 64.4K | 125.2K | 617.0K | 10.62% | ↗ |
| 25 | 2016 | John Harris, VP and General Manager of Cell Therapy | 361.8K | — | — | 65.5K | 64.4K | 125.2K | 617.0K | 10.62% | ↗ |
| 26 | 2016 | Tiago M. Girão, VP of Finance, Chief Financial Officer and Chief Accounting Officer | 265.0K | — | — | 65.5K | 79.6K | — | 410.1K | 15.98% | ↗ |
| 27 | 2016 | Tiago M. Girao, VP of Finance, Chief Financial Officer and Chief Accounting Officer | 265.0K | — | — | 65.5K | 79.6K | — | 410.1K | 15.98% | ↗ |
| 28 | 2015 | Tiago M. Girão, VP of Finance and Chief Financial Officer (PFO) | — | — | — | 554.3K | 182.3K | — | 1.17M | 47.22% | ↗ |
| 29 | 2015 | Marc H. Hedrick, M.D., President and Chief Executive Officer | 450.0K | — | 80.2K | 115.2K | 200.5K | — | 845.8K | 23.10% | ↗ |
| 30 | 2015 | Ken Kleinhenz Vice President, Global Regulatory Affairs | 306.5K | — | — | 76.8K | — | — | 524.4K | 14.65% | ↗ |
| 31 | 2015 | Marc H. Hedrick, M.D., President and Chief Executive Officer (PEO) | 450.0K | — | — | — | — | — | 450.0K | 0.00% | ↗ |
| 32 | 2015 | Tiago M. Girão, VP of Finance, Chief Financial Officer and Chief Accounting Officer | 265.0K | — | 40.1K | 57.6K | 69.6K | — | 432.2K | 22.60% | ↗ |
| 33 | 2015 | Steven Kesten, M.D., Executive Vice President and Chief Medical Officer | 265.0K | — | 40.1K | — | — | — | 305.1K | 13.14% | ↗ |
| 34 | 2015 | Seijiro Shirahama, Chairman, Cytori Therapeutics, K.K. | — | — | — | 137.6K | 50.0K | — | 266.6K | 51.59% | ↗ |
| 35 | 2015 | John D. Harris, VP and General Manager of Cell Therapy | 88.2K | — | — | 124.0K | 26.0K | 19.6K | 257.8K | 48.10% | ↗ |
| 36 | 2014 | Marc H. Hedrick, M.D., President and Chief Executive Officer (PEO) | — | — | 80.2K | 115.2K | 200.5K | — | 845.8K | 23.10% | ↗ |
| 37 | 2014 | Mark E. Saad, Former Chief Financial Officer | 371.8K | — | — | 211.8K | 24.5K | 44.4K | 608.1K | 34.82% | ↗ |
| 38 | 2014 | Steven Kesten, M.D., Executive Vice President and Chief Medical Officer | — | — | — | 57.6K | 69.6K | 68.4K | 432.2K | 13.33% | ↗ |
| 39 | 2014 | Tiago M. Girão, VP of Finance and Chief Financial Officer (PFO) | 406.6K | — | — | — | — | — | 406.6K | 0.00% | ↗ |
| 40 | 2014 | Ken Kleinhenz Vice President, Global Regulatory Affairs | — | — | — | — | 87.7K | — | 87.7K | 0.00% | ↗ |
| 41 | 2014 | Seijiro Shirahama, Chairman, Cytori Therapeutics, K.K. | — | — | 53.4K | — | — | — | 53.4K | 100.00% | ↗ |
| 42 | 2014 | Clyde W. Shores, Former Executive Vice President Marketing Sales | — | — | — | — | — | — | — | — | ↗ |
| 43 | 2014 | Christopher J. Calhoun, Former Chief Executive Officer | — | — | — | — | — | — | — | — | ↗ |
| 44 | 2014 | Seijiro Shirahama, President- Asia Pacific | — | — | — | — | — | — | — | — | ↗ |
| 45 | 2014 | Marc H. Hedrick, President and Chief Executive Officer (PEO) | — | — | — | — | — | — | — | — | ↗ |
| 46 | 2013 | Christopher J. Calhoun, Former Chief Executive Officer (PEO) | 467.9K | — | — | 635.3K | 82.5K | — | 1.19M | 53.58% | ↗ |
| 47 | 2013 | Marc H. Hedrick, President and Chief Executive Officer (PEO) | 437.4K | — | — | 554.3K | 182.3K | — | 1.17M | 47.22% | ↗ |
| 48 | 2013 | Tiago M. Girão, VP of Finance and Chief Financial Officer (PFO) | — | — | — | 465.9K | 89.1K | — | 961.6K | 48.45% | ↗ |
| 49 | 2013 | Marc H. Hedrick, President and Chief Executive Officer | 406.6K | — | — | 465.9K | 89.1K | — | 961.6K | 48.45% | ↗ |
| 50 | 2013 | Mark E. Saad, Chief Financial Officer (PFO) | 389.9K | — | — | 381.2K | 35.7K | — | 806.7K | 47.25% | ↗ |
| 51 | 2013 | Clyde W. Shores, Former Executive Vice President Marketing Sales | 333.3K | — | 178.3K | 271.2K | 113.9K | — | 786.8K | 57.12% | ↗ |
| 52 | 2013 | Steven Kesten, M.D., Executive Vice President and Chief Medical Officer | 333.3K | — | — | 271.2K | 38.9K | 143.4K | 786.8K | 34.47% | ↗ |
| 53 | 2013 | Ken Kleinhenz Vice President, Global Regulatory Affairs | 400.0K | — | 26.7K | 310.9K | — | — | 774.6K | 43.58% | ↗ |
| 54 | 2013 | Clyde W. Shores, Executive Vice President Marketing Sales | 329.5K | — | — | 254.1K | 25.2K | 35.0K | 643.8K | 39.47% | ↗ |
| 55 | 2013 | Christopher J. Calhoun, Former Chief Executive Officer | 367.0K | — | — | 208.6K | 50.5K | 35.0K | 626.0K | 33.32% | ↗ |
| 56 | 2013 | Marc H. Hedrick, M.D., President and Chief Executive Officer (PEO) | 437.4K | — | — | — | — | — | 437.4K | 0.00% | ↗ |
| 57 | 2013 | Steven Kesten, M.D., Executive Vice President and Chief Medical Officer | 79.1K | — | — | — | — | — | 79.1K | 0.00% | ↗ |
| 58 | 2013 | Seijiro Shirahama, President- Asia Pacific | — | — | — | — | — | — | — | — | ↗ |
| 59 | 2013 | Mark E. Saad, Former Chief Financial Officer | — | — | — | — | — | — | — | — | ↗ |
| 60 | 2013 | Seijiro Shirahama, Chairman, Cytori Therapeutics, K.K. | — | — | — | — | — | — | — | — | ↗ |
| 61 | 2012 | Christopher J. Calhoun, Chief Executive Officer (PEO) | 467.9K | — | 293.3K | 484.0K | 110.0K | — | 1.36M | 57.36% | ↗ |
| 62 | 2012 | Christopher J. Calhoun, Former Chief Executive Officer (PEO) | 467.9K | — | 293.3K | 484.0K | 110.0K | — | 1.36M | 57.36% | ↗ |
| 63 | 2012 | Marc H. Hedrick, President | 406.6K | — | 212.8K | 242.0K | 76.4K | — | 937.8K | 48.49% | ↗ |
| 64 | 2012 | Tiago M. Girão, VP of Finance and Chief Financial Officer (PFO) | 406.6K | — | — | 242.0K | 76.4K | — | 937.8K | 25.80% | ↗ |
| 65 | 2012 | Marc H. Hedrick, President and Chief Executive Officer | 406.6K | — | 212.8K | 242.0K | 76.4K | — | 937.8K | 48.49% | ↗ |
| 66 | 2012 | Seijiro N. Shirahama, President – Asia Pacific | 454.4K | — | 178.3K | 84.2K | 82.8K | — | 799.7K | 32.82% | ↗ |
| 67 | 2012 | Mark E. Saad, Former Chief Financial Officer | 454.4K | — | — | 84.2K | 82.8K | 129.6K | 779.7K | 10.80% | ↗ |
| 68 | 2012 | Seijiro Shirahama, President- Asia Pacific | 400.0K | — | — | 310.9K | 63.8K | — | 774.6K | 40.13% | ↗ |
| 69 | 2012 | Mark E. Saad, Chief Financial Officer (PFO) | 389.9K | — | 184.0K | 84.2K | 64.1K | — | 722.3K | 37.13% | ↗ |
| 70 | 2012 | Clyde W. Shores, Executive Vice President Marketing Sales | 329.5K | — | 178.3K | 84.2K | 65.3K | 44.4K | 701.6K | 37.41% | ↗ |
| 71 | 2012 | Christopher J. Calhoun, Former Chief Executive Officer | — | — | 178.3K | — | — | — | 178.3K | 100.00% | ↗ |
| 72 | 2012 | Steven Kesten, M.D., Executive Vice President and Chief Medical Officer | — | — | — | — | — | 68.4K | 68.4K | 0.00% | ↗ |
| 73 | 2012 | Clyde W. Shores, Former Executive Vice President Marketing Sales | — | — | — | — | — | 25.3K | 25.3K | 0.00% | ↗ |
| 74 | 2012 | Marc H. Hedrick, President and Chief Executive Officer (PEO) | — | — | — | — | — | — | — | — | ↗ |
| 75 | 2012 | Steven Kesten, M.D., Executive Vice President and Chief Medical Officer | — | — | — | — | — | — | — | — | ↗ |
| 76 | 2011 | Christopher J. Calhoun, Former Chief Executive Officer (PEO) | 456.5K | — | 292.5K | — | 140.4K | 10.2K | 1.15M | 25.38% | ↗ |
| 77 | 2011 | Christopher J. Calhoun, Chief Executive Officer (PEO) | 456.5K | — | 292.5K | 252.9K | 140.4K | 10.2K | 1.15M | 47.32% | ↗ |
| 78 | 2011 | Marc H. Hedrick, President | 396.8K | — | 214.5K | — | 97.6K | — | 894.2K | 23.98% | ↗ |
| 79 | 2011 | Marc H. Hedrick, President and Chief Executive Officer | 396.8K | — | 214.5K | — | 97.6K | — | 894.2K | 23.98% | ↗ |
| 80 | 2011 | Seijiro N. Shirahama, President – Asia Pacific | 441.9K | — | 185.2K | 160.1K | 69.3K | — | 856.6K | 40.32% | ↗ |
| 81 | 2011 | Seijiro N. Shirahama, President – Asia Pacific | 441.9K | — | 185.2K | 160.1K | 69.3K | — | 856.6K | 40.32% | ↗ |
| 82 | 2011 | Mark E. Saad, Chief Financial Officer (PFO) | 380.5K | — | 195.0K | 168.6K | 81.9K | — | 825.9K | 44.02% | ↗ |
| 83 | 2011 | Mark E. Saad, Chief Financial Officer (PFO) | 380.5K | — | 195.0K | — | 81.9K | — | 825.9K | 23.61% | ↗ |
| 84 | 2011 | Clyde W. Shores, Executive Vice President Marketing Sales | 203.9K | — | — | 269.2K | 37.4K | 152.1K | 662.6K | 40.63% | ↗ |
| 85 | 2011 | Clyde W. Shores, Executive Vice President Marketing Sales | 203.9K | — | — | — | 37.4K | 152.1K | 662.6K | 0.00% | ↗ |
| 86 | 2011 | Steven Kesten, M.D., Executive Vice President and Chief Medical Officer | — | — | — | — | — | — | — | — | ↗ |
| 87 | 2010 | Christopher J. Calhoun, Chief Executive Officer (PEO) | 439.7K | — | — | — | 172.6K | — | 1.22M | 0.00% | ↗ |
| 88 | 2010 | Marc H. Hedrick, President | 382.1K | — | — | — | 115.3K | — | 945.5K | 0.00% | ↗ |
| 89 | 2010 | Mark E. Saad, Chief Financial Officer (PFO) | 366.4K | — | — | — | 110.0K | — | 883.7K | 0.00% | ↗ |
| 90 | 2010 | Mark E. Saad, Chief Financial Officer (PFO) | 366.4K | — | — | 407.3K | 110.0K | — | 883.7K | 46.09% | ↗ |
| 91 | 2010 | Seijiro N. Shirahama, President – Asia Pacific | 381.9K | — | — | — | 87.9K | — | 856.8K | 0.00% | ↗ |
| 92 | 2010 | Seijiro N. Shirahama, President – Asia Pacific | 381.9K | — | — | 387.0K | 87.9K | — | 856.8K | 45.16% | ↗ |
| 93 | 2010 | Douglas Arm, Ph.D., Sr. Vice President - Operations | 276.8K | — | — | 203.7K | 57.2K | — | 537.7K | 37.88% | ↗ |
| 94 | 2010 | Clyde W. Shores, Executive Vice President Marketing Sales | — | — | — | — | — | — | — | — | ↗ |
| 95 | 2010 | Clyde W. Shores, Executive Vice President Marketing Sales | — | — | — | — | — | — | — | — | ↗ |
| 96 | 2009 | Christopher J. Calhoun, Chief Executive Officer (PEO) | 422.8K | — | — | 269.8K | 174.7K | — | 867.3K | 31.10% | ↗ |
| 97 | 2009 | Christopher J. Calhoun, Chief Executive Officer (PEO) | 422.8K | — | — | 269.8K | 174.7K | — | 867.3K | 31.10% | ↗ |
| 98 | 2009 | Marc H. Hedrick, President | 367.4K | — | — | 202.3K | 113.9K | — | 683.6K | 29.59% | ↗ |
| 99 | 2009 | Mark E. Saad, Chief Financial Officer (PFO) | 352.3K | — | — | 188.8K | 110.8K | — | 652.0K | 28.96% | ↗ |
| 100 | 2009 | Mark E. Saad, Chief Financial Officer (PFO) | 352.3K | — | — | 188.8K | 110.8K | — | 652.0K | 28.96% | ↗ |
| 101 | 2009 | Seijiro N. Shirahama, President – Asia Pacific | 260.0K | — | — | 175.3K | 48.9K | — | 484.3K | 36.21% | ↗ |
| 102 | 2009 | Seijiro N. Shirahama, President – Asia Pacific | 260.0K | — | — | 175.3K | 48.9K | — | 484.3K | 36.21% | ↗ |
| 103 | 2009 | Douglass Arm, Ph.D., Sr. Vice President - Operations | 237.1K | — | — | 120.4K | 58.4K | — | 416.0K | 28.95% | ↗ |
| 104 | 2009 | Douglas Arm, Ph.D., Sr. Vice President - Operations | 237.1K | — | — | 120.4K | 58.4K | — | 416.0K | 28.95% | ↗ |
| 105 | 2009 | Clyde W. Shores, Executive Vice President Marketing Sales | — | — | — | — | — | — | — | — | ↗ |
| 106 | 2008 | Christopher J. Calhoun, Chief Executive Officer (PEO) | 420.0K | — | — | 231.7K | — | 14.8K | 666.5K | 34.76% | ↗ |
| 107 | 2008 | Marc H. Hedrick, President | 384.5K | — | — | 163.5K | — | 117.0K | 665.0K | 24.59% | ↗ |
| 108 | 2008 | Mark E. Saad, Chief Financial Officer (PFO) | 350.0K | — | — | 149.9K | — | — | 499.9K | 29.99% | ↗ |
| 109 | 2008 | Seijiro N. Shirahama, President – Asia Pacific | 260.0K | — | — | 149.9K | — | — | 409.9K | 36.57% | ↗ |
| 110 | 2008 | Douglass Arm, Ph.D., Sr. Vice President - Operations | 225.0K | — | — | 54.5K | — | — | 279.3K | 19.52% | ↗ |
| 111 | 2008 | Bruce A. Reuter, Sr. Vice President – Int’l Sales, Marketing Distribution | — | — | — | — | 99.2K | — | 99.2K | 0.00% | ↗ |
| 112 | 2007 | Christopher J. Calhoun, Chief Executive Officer (PEO) | 420.0K | — | — | 267.3K | 172.2K | 10.5K | 870.0K | 30.72% | ↗ |
| 113 | 2007 | Marc H. Hedrick, President | 372.3K | — | — | 190.9K | 124.1K | — | 687.3K | 27.77% | ↗ |
| 114 | 2007 | Mark E. Saad, Chief Financial Officer (PFO) | 350.0K | — | — | 190.9K | 99.2K | — | 640.1K | 29.82% | ↗ |
| 115 | 2007 | Bruce A. Reuter, Sr. Vice President – Int’l Sales, Marketing Distribution | 350.0K | — | — | 181.7K | — | — | 531.7K | 34.17% | ↗ |
| 116 | 2007 | Seijiro N. Shirahama, President – Asia Pacific | 239.2K | — | — | 194.6K | 55.3K | — | 489.0K | 39.79% | ↗ |
| 117 | 2007 | Douglass Arm, Ph.D., Sr. Vice President - Operations | 220.8K | — | — | 76.4K | 39.2K | — | 336.3K | 22.70% | ↗ |
| 118 | 2006 | Marc H. Hedrick, President | 395.0K | — | — | 251.0K | — | 18.6K | 786.3K | 31.91% | ↗ |
| 119 | 2006 | Seijiro N. Shirahama, President – Asia Pacific | 331.7K | — | — | 170.8K | — | — | 601.1K | 28.41% | ↗ |
| 120 | 2006 | Seijiro N. Shirahama, Sr. Vice President - Asia Pacific | 214.8K | — | — | 227.6K | 36.4K | — | 481.0K | 47.33% | ↗ |
| 121 | 2006 | John Ransom, Vice President - Regenerative Cell Tech. | 183.3K | — | — | 208.1K | 24.0K | 10.8K | 426.3K | 48.83% | ↗ |
| 122 | 2006 | Christopher J. Calhoun, Chief Executive Officer (PEO) | — | — | — | — | 172.2K | — | 172.2K | 0.00% | ↗ |
| 123 | 2006 | Bruce A. Reuter, Sr. Vice President – Int’l Sales, Marketing Distribution | — | — | — | — | 63.4K | 10.8K | 74.3K | 0.00% | ↗ |
| 124 | 2006 | Mark E. Saad, Chief Financial Officer (PFO) | — | — | — | — | — | — | — | — | ↗ |
| 125 | 2005 | Christopher J. Calhoun Chief Executive Officer | 369.8K | 79.9K | — | 100.0K | — | — | 449.7K | 22.24% | ↗ |
| 126 | 2005 | Marc H. Hedrick, MD President | 289.8K | 50.0K | — | 70.0K | — | — | 339.8K | 20.60% | ↗ |
| 127 | 2005 | Mark E. Saad Chief Financial Officer | 308.6K | 12.5K | — | 70.0K | — | — | 321.1K | 21.80% | ↗ |
| 128 | 2005 | Charles E. Galetto Senior Vice President – Finance and Administration, and Treasurer | 216.3K | 21.5K | — | 35.0K | — | — | 237.8K | 14.72% | ↗ |
| 129 | 2005 | Bruce A. Reuter Senior Vice President – Business Development | 201.4K | 18.3K | — | 35.0K | — | — | 219.7K | 15.93% | ↗ |
| 130 | 2004 | Christopher J. Calhoun Chief Executive Officer | 345.0K | 135.0K | — | 75.0K | — | 3.2K | 483.2K | 15.52% | ↗ |
| 131 | 2004 | Marc H. Hedrick, MD President | 253.8K | 60.0K | — | 50.0K | — | — | 313.8K | 15.94% | ↗ |
| 132 | 2004 | Sharon V. Schulzki Chief Operating Officer | 235.4K | 37.8K | — | — | — | 13.5K | 286.6K | 0.00% | ↗ |
| 133 | 2004 | Bruce A. Reuter Senior Vice President — Business Development | 182.4K | 30.9K | — | — | — | 13.9K | 227.3K | 0.00% | ↗ |
| 134 | 2004 | Bruce A. Reuter Senior Vice President – Business Development | 182.4K | 30.9K | — | 25.0K | — | — | 213.4K | 11.72% | ↗ |
| 135 | 2004 | Charles E. Galetto Senior Vice President – Finance and Administration, and Treasurer | 180.0K | 30.9K | — | 25.0K | — | — | 210.9K | 11.85% | ↗ |
| 136 | 2004 | Mark E. Saad Chief Financial Officer | 115.0K | — | — | 190.0K | — | — | 115.0K | 165.21% | ↗ |
| 137 | 2003 | Ari E. Bizimis former Chief Financial Officer | 200.0K | 62.0K | — | 75.0K | — | 261.0K | 523.0K | 14.34% | ↗ |
| 138 | 2003 | Sharon V. Schulzki Chief Operating Officer | 180.0K | 30.2K | — | — | — | 273.4K | 483.6K | 0.00% | ↗ |
| 139 | 2003 | Sharon V. Schulzki Senior Vice President—Marketing Development—Biomaterials | 180.0K | 30.2K | — | 35.0K | — | 273.4K | 483.6K | 7.24% | ↗ |
| 140 | 2003 | Christopher J. Calhoun President, Chief Executive Officer and Secretary | 240.0K | 120.6K | — | 200.0K | — | 20.9K | 381.5K | 52.43% | ↗ |
| 141 | 2003 | Christopher J. Calhoun Chief Executive Officer | 240.0K | 120.6K | — | — | — | 3.2K | 363.8K | 0.00% | ↗ |
| 142 | 2003 | Marc H. Hedrick, MD President | 200.0K | 26.8K | — | — | — | — | 226.8K | 0.00% | ↗ |
| 143 | 2003 | Charles E. Galetto Senior Vice President, Finance and Administration and Treasurer | 165.0K | 27.6K | — | 35.0K | — | 15.6K | 208.3K | 16.81% | ↗ |
| 144 | 2003 | Bruce A. Reuter Senior Vice President—International Business | 165.0K | 27.6K | — | 35.0K | — | 14.6K | 207.2K | 16.89% | ↗ |
| 145 | 2003 | Bruce A. Reuter Senior Vice President — Business Development | 165.0K | 27.6K | — | — | — | 14.6K | 207.2K | 0.00% | ↗ |
| 146 | 2003 | Charles E. Galetto Senior Vice President – Finance and Administration, and Treasurer | 165.0K | 27.6K | — | 35.0K | — | — | 192.6K | 18.17% | ↗ |
| 147 | 2003 | Bruce A. Reuter Senior Vice President – Business Development | 165.0K | 27.6K | — | 35.0K | — | — | 192.6K | 18.17% | ↗ |
| 148 | 2003 | Mark E. Saad Chief Financial Officer | — | — | — | — | — | — | — | — | ↗ |
| 149 | 2002 | Christopher J. Calhoun Chief Executive Officer | 190.0K | 40.0K | — | — | — | 15.2K | 245.2K | 0.00% | ↗ |
| 150 | 2002 | Christopher J. Calhoun President, Chief Executive Officer and Secretary | 190.0K | 40.0K | — | 205.0K | — | 15.2K | 245.2K | 83.61% | ↗ |
| 151 | 2002 | Ari E. Bizimis Chief Financial Officer | 187.6K | 34.3K | — | 110.0K | — | 9.6K | 231.5K | 47.52% | ↗ |
| 152 | 2002 | Ari E. Bizimis former Chief Financial Officer | 187.6K | 34.3K | — | 110.0K | — | 9.6K | 231.5K | 47.52% | ↗ |
| 153 | 2002 | Sharon V. Schulzki Senior Vice President—Marketing Development—Biomaterials | 163.3K | 30.0K | — | 25.0K | — | 11.6K | 204.9K | 12.20% | ↗ |
| 154 | 2002 | Sharon V. Schulzki Chief Operating Officer | 163.3K | 30.0K | — | — | — | 11.6K | 204.9K | 0.00% | ↗ |
| 155 | 2002 | Charles E. Galetto Senior Vice President, Finance and Administration and Treasurer | 152.5K | 26.0K | — | 30.0K | — | 12.7K | 191.2K | 15.69% | ↗ |
| 156 | 2002 | Charles E. Galetto Senior Vice President – Finance and Administration, and Treasurer | 152.5K | 26.0K | — | — | — | 12.7K | 191.2K | 0.00% | ↗ |
| 157 | 2002 | Bruce A. Reuter Senior Vice President—International Business | 152.5K | 25.0K | — | 30.0K | — | 11.6K | 189.1K | 15.86% | ↗ |
| 158 | 2002 | Bruce A. Reuter Senior Vice President — Business Development | 152.5K | 25.0K | — | — | — | 11.6K | 189.1K | 0.00% | ↗ |
| 159 | 2002 | Marc H. Hedrick, MD President | 25.0K | — | — | — | — | 1.5K | 26.5K | 0.00% | ↗ |
| 160 | 2001 | Christopher J. Calhoun President, Chief Executive Officer and Secretary | 180.0K | 50.8K | — | 200.0K | — | 15.2K | 246.0K | 81.31% | ↗ |
| 161 | 2001 | Christopher J. Calhoun Chief Executive Officer and Secretary | 180.0K | 40.0K | — | 200.0K | — | 20.3K | 240.3K | 83.22% | ↗ |
| 162 | 2001 | Michael Simpson President | 166.2K | 30.0K | — | 100.0K | — | 12.2K | 208.4K | 47.99% | ↗ |
| 163 | 2001 | Ari E. Bizimis Chief Financial Officer | 160.0K | 35.0K | — | 50.0K | — | 9.6K | 204.6K | 24.44% | ↗ |
| 164 | 2001 | Ari E. Bizimis former Chief Financial Officer | 160.0K | 35.0K | — | 50.0K | — | 9.6K | 204.6K | 24.44% | ↗ |
| 165 | 2001 | Charles E. Galetto Senior Vice President, Finance and Administration and Treasurer | 150.0K | 28.1K | — | 20.0K | — | 11.6K | 189.7K | 10.54% | ↗ |
| 166 | 2001 | Sharon V. Schulzki Senior Vice President—Marketing Development—Biomaterials | 162.0K | 15.0K | — | 200.0K | — | 9.6K | 186.6K | 107.18% | ↗ |
| 167 | 2001 | Bruce A. Reuter Senior Vice President—International Business | 152.0K | — | — | 135.0K | — | 11.9K | 163.9K | 82.37% | ↗ |
| 168 | 2000 | Christopher J. Calhoun President, Chief Executive Officer and Secretary | 177.3K | 50.8K | — | 62.5K | — | 12.8K | 240.9K | 25.94% | ↗ |
| 169 | 2000 | Christopher J. Calhoun Chief Executive Officer and Secretary | 177.3K | 50.8K | — | 62.5K | — | 12.8K | 240.9K | 25.94% | ↗ |
| 170 | 2000 | Michael Simpson President | 168.3K | 46.5K | — | 68.8K | — | 9.6K | 224.4K | 30.63% | ↗ |
| 171 | 2000 | Ari E. Bizimis Chief Financial Officer | 120.0K | 36.0K | — | 275.0K | — | 7.2K | 163.2K | 168.50% | ↗ |
| 172 | 2000 | Charles E. Galetto Senior Vice President, Finance and Administration and Treasurer | 102.9K | 38.1K | — | 100.0K | — | 6.6K | 147.6K | 67.75% | ↗ |
| 173 | 2000 | Sharon V. Schulzki Senior Vice President—Marketing Development—Biomaterials | 68.8K | — | — | 175.0K | — | 4.4K | 73.2K | 239.23% | ↗ |
| 174 | 1999 | Michael Simpson President | 165.0K | 41.1K | — | 55.0K | — | 9.6K | 215.7K | 25.50% | ↗ |
| 175 | 1999 | Christopher J. Calhoun Chief Executive Officer and Secretary | 145.8K | 41.1K | — | 250.0K | — | 7.4K | 194.2K | 128.72% | ↗ |
CEO compensation breakdown
Proxy statements
Proxy statements (DEF 14A)
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Marc H. Hedrick | President, Chief Executive Officer & Director | 934.2K | — |
| Andrew J. Sims | Vice President & Chief Financial Officer | 556.7K | male |
| Desiree Smith | Corporate Controller | — | female |
| Eric J. Daniels | Chief Development Officer | — | — |
| Russ Havranek | Executive Vice President of Commercial and Corporate Strategy | — | male |
| Russell W. Bradley | President & GM of CNSide Diagnostics, LLC | — | male |
ESG Rating
ESG Score History BIOTECHNOLOGY
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for PSTV
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
